So-called "clinical equipoise" and the argument from design.

Area of Science:

• Medical ethics
• Clinical trial design
• Research methodology

Background:

• The concept of clinical equipoise is widely used to justify randomized clinical trials (RCTs).
• Freedman's formulation of clinical equipoise has been particularly influential.
• However, significant ethical and methodological concerns have been raised regarding its adequacy.

Purpose of the Study:

• To critically review and expand upon arguments challenging the moral legitimacy of using clinical equipoise to justify RCTs.
• To explain the reasons behind the continued acceptance of the clinical equipoise approach despite its flaws.
• To highlight the misleading framing and conflation of concepts within Freedman's original discussion.

Main Methods:

• Critical analysis of existing arguments concerning clinical equipoise.
• Review of Freedman's original formulation and its implications.
• Examination of the conflation between clinical equipoise and community equipoise.
• Distinction between individual patient decisions and policy decisions in research ethics.

Main Results:

• Freedman's clinical equipoise criterion is inadequate as a guide for the moral legitimacy of RCTs.
• The approach conflates distinct versions of clinical and community equipoise, creating a misleading impression of a unified solution.
• Crucial distinctions, such as that between individual patient and policy decisions, are overlooked, obscuring fundamental flaws.

Conclusions:

• The clinical equipoise framework, as presented by Freedman, is ethically and methodologically flawed.
• A more rigorous and nuanced ethical framework is needed for the justification of randomized clinical trials.
• Attention must be paid to the distinction between individual patient consent and broader policy implications in research ethics.